TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · USD

$1.57

-0.06 (-3.7%)· Recorded snapshot

Market cap	26.6M
Net income (ttm)	-46.3M
EPS (ttm)	-$51.1
Shares out	16.9M
Volume	29,550.101
Beta	1.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -46.3M
EPS (ttm): -$51.1
Market cap: 26.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-59.3

P25 -113.8P50 -46.5P75 -0.9

ROIC-21.8

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RNAZ indicators

Market & fundamental data

Available fields

179

Groups with data

Currency

USD

Showing 179 of 179 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001829635
Company name	TransCode Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	89357L501
Earnings date	2026-08-14
Earnings time	amc
Employees	12
Employees change	5
Employees growth	71.43%
Enterprise value	$18.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
Industry	Biotechnology
IPO date	2021-07-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US89357L5012
Last 10-K release date	2026-04-15
Last earnings date	2026-08-14
Last refreshed	2026-11-04
Last stock split date	2025-05-15
Last stock split type	Reverse
Market cap	$26.6M
Market cap category	Nano-Cap
Next earnings date	2027-02-13
Options	No
Price	$1.57
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	RNAZ
U.S. state	Massachusetts
Website	https://www.transcodetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3,253.29%
FCF / EV yield	-119.96%
FCF yield	-85.07%
P/B ratio	0.19x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3.9M
ROA	-19.9%
ROA (5Y)	-93.96%
ROCE	-17.42%
ROE	-59.28%
ROIC	-21.84%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-6,660
Depreciation and amortization	$97,434
EBIT	$-25.4M
EBITDA	$-25.3M
EPS	$-51.08
FCF per share	$-1.34
Financing cash flow	$23.6M
Free cash flow	$-22.6M
Free cash flow minus SBC	$-22.8M
Income taxes	$457,677
Investing cash flow	$-4,436
Net borrowing	$950,000
Net cash flow	$1M
Net income	$-46.3M
Operating cash flow minus SBC	$-22.8M
Operating income	$-25.4M
Stock-based compensation	$196,189

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-27.38
Debt / equity	0
Goodwill	$25.7M
Interest coverage	-3,900.25
Long-term assets	$140.4M
Long-term liabilities	$7.3M
Net cash (debt)	$7.7M
Net cash / market cap	29.08%
Net cash growth	4.83%
Net debt / equity	-0.06
Piotroski F-Score	1
Property, plant and equipment	$322,809
Shareholders' equity	$138.4M
Tangible book value	$-167.7M
Tangible book value per share	$-165.82
Total assets	$151M
Total cash	$8.4M
Total debt	$652,411
Total liabilities	$12.7M
WACC	10.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$10.6M
Current liabilities	$5.4M
Current ratio	1.97
Net working capital	$-2.5M
Quick ratio	1.55
Working capital	$5.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-246.69%
Dividend yield	0%
Shareholder yield	-246.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.90
1D price change	-3.68%
1W price change	-5.99%
1W total return	-5.99%
1Y price change	-85.98%
1Y return CAGR	-86%
1Y total return	-85.98%
20-day SMA	$1.70
200-day SMA	$6.08
3M price change	-65.57%
3M total return	-65.57%
3Y price change	-99.99%
3Y return CAGR	-95.11%
3Y total return	-99.99%
50-day SMA	$1.79
50-day SMA vs 200-day SMA	50under200
52-week high	$12.60
52-week high date	2026-01-26
52-week low	$1.50
52-week low date	2026-11-03
5Y price change	-100%
5Y return CAGR	-94.21%
5Y total return	-100%
6M price change	-79.95%
6M total return	-79.95%
All-time high	$5,174,452.99
All-time high date	2021-07-09
All-time low	$1.50
All-time low date	2026-11-03
Average true range (ATR)	$0.17
Average volume	32.3K
Beta (1Y)	1.01
Beta (2Y)	2.63
Beta (5Y)	1.27
Change from 52-week high	-87.54%
Change from 52-week low	4.67%
Change from all-time high	-100%
Change from all-time low	4.67%
Change from open	-1.88%
Day's gap	-1.84%
Dollar volume	$46,394
High price	$1.65
Low price	$1.50
Monthly RSI	22.65
Open price	$1.60
Position in 52-week range	46.67%
Premarket change	1.27%
Premarket close	$1.57
Premarket price	$1.59
Previous close	$1.63
Price vs 150-day SMA	-67.96%
Price vs 20-day SMA	-7.86%
Price vs 200-day SMA	-74.18%
Price vs 50-day SMA	-12.14%
Relative volume	0.91
Return from IPO open	-100%
Return from IPO price	-60.75%
RSI	38.09
Sharpe ratio	-1.7
Sharpe ratio (3Y)	-1.08
Sharpe ratio (5Y)	-0.6
Sortino ratio	-2.45
Sortino ratio (3Y)	-1.5
Sortino ratio (5Y)	-1.11
Volume	29.6K
Weekly RSI	29.15
YTD price change	-77.01%
YTD total return	-77.01%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2.2M
Float percentage	12.72%
Shares change (QoQ)	4.39%
Shares change (YoY)	246.69%
Shares held by insiders	2.03%
Shares held by institutions	0.52%
Shares outstanding	16.9M
Short % of float	2.55%
Short % of shares	0.32%
Short ratio	1 days

Deeper analysis on RNAZ

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RNAZ report

Is a complete RNAZ research report available?

No complete published report is available for TransCode Therapeutics, Inc. (RNAZ) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TransCode Therapeutics, Inc. (RNAZ)

Price

Financial snapshot

Fair-value bridge

Latest news · RNAZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RNAZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RNAZ

Frequently asked questions